The recently developed molecule xeruborbactam could help against antibiotic resistance in certain bacteria, but not all, as a new study from the University of Freiburg (Unifr) shows.
Unifr announced on Wednesday that the study puts earlier, more optimistic assessments into perspective. Despite this, the university described the molecule as a “stage victory in the fight against antibiotic resistance”.
Some bacteria produce protective enzymes, so-called metallo-β-lactamases, to protect themselves against certain antibiotics. This makes antibiotics ineffective against these bacteria. To solve this problem, the pharmaceutical industry has recently developed the molecule xeruborbactam. This molecule blocks the effect of the protective enzymes and can restore the effect of antibiotics.
“Not yet at the finish line”
The Fribourg researchers have now investigated the effectiveness of this molecule against two resistant bacteria circulating in Switzerland: Escherichia coli, a major cause of urinary tract infections, and Pseudomonas aeruginosa, which can cause pneumonia.
The results were published in the journal Antimicrobial Agents and Chemotherapy.
The drug was found to be effective against E. coli bacteria. However, according to the researchers, it was significantly less effective against the bacterium Pseudomonas aeruginosa.
“These bacteria have an efficient defense mechanism: a kind of pump that not only transports the antibiotics but also the new inhibitor out of the cell before they can reach their targets,” explains study leader Laurent Poirel.
Contrary to the researchers’ expectations, certain strains of this bacterium were even resistant to the effect of the new drug.
“We have not yet reached our goal and the continuous search for even more effective molecules remains crucial,” concluded Poirel.
More
More
Rise in use of antibiotics in Switzerland
This content was published on
The consumption of antibiotics has risen in Switzerland since the Covid-19 pandemic. However, compared to other European countries the Alpine country has one of the lowest levels of antibiotic usage.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
Popular Stories
More
Life & Aging
Switzerland no longer wants to foot the bill for ‘suicide tourism’
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
Switzerland to collect data from non-Schengen visitors
This content was published on
The data of travellers from non-Schengen countries will be automatically recorded at the borders of member countries, also Switzerland.
Swiss air traffic controller in red after year of breakdowns
This content was published on
Swiss air traffic controller Skyguide ended 2024, a year marked by repeated breakdowns, with a loss of almost CHF19 million.
Ex-FIFA boss Blatter declares innocence in appeal trial
This content was published on
Former FIFA boss Joseph 'Sepp' Blatter has opened his defence at a Swiss appeal trial which is hearing allegations of fraud.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.